Predictive Oncology (NASDAQ:POAI) vs. Safe Pro Group Inc. Common Stock (NASDAQ:SPAI) Head-To-Head Analysis

Safe Pro Group Inc. Common Stock (NASDAQ:SPAI) and Predictive Oncology (NASDAQ:POAI) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.

Valuation and Earnings

This table compares Safe Pro Group Inc. Common Stock and Predictive Oncology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Safe Pro Group Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
Predictive Oncology	$1.78 million	6.07	-$13.98 million	($3.05)	-0.53

Safe Pro Group Inc. Common Stock has higher earnings, but lower revenue than Predictive Oncology.

Profitability

This table compares Safe Pro Group Inc. Common Stock and Predictive Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Safe Pro Group Inc. Common Stock	N/A	N/A	N/A
Predictive Oncology	-1,012.32%	-286.30%	-122.11%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Safe Pro Group Inc. Common Stock and Predictive Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Safe Pro Group Inc. Common Stock	0	0	0	0	0.00
Predictive Oncology	0	1	0	0	2.00

Predictive Oncology has a consensus price target of $3.00, suggesting a potential upside of 85.19%. Given Predictive Oncology’s stronger consensus rating and higher possible upside, analysts clearly believe Predictive Oncology is more favorable than Safe Pro Group Inc. Common Stock.

Institutional & Insider Ownership

9.0% of Predictive Oncology shares are held by institutional investors. 3.4% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Predictive Oncology beats Safe Pro Group Inc. Common Stock on 5 of the 8 factors compared between the two stocks.

About Safe Pro Group Inc. Common Stock

Safe Pro Group, Inc. engages in the provision and acquisition of security and protection products. Its products include Artificial Intelligence (AI) and Machine Learning (ML) software technology and photogrammetry analysis tools, bullet and blast resistant personal protection equipment, and aerial managed services and mission-critical uncrewed solutions. The firm operates through the following segments: Safe-PRO USA, Airborne Response, and Safe Pro AI. The company was founded by Daniyel Erdberg on December 15, 2021 and is headquartered in Aventura, FL.

About Predictive Oncology

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.